Novo Nordisk A/S | TalkMarkets

Latest Posts

Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?

Article By: Fred Fuld III

Thursday, May 9, 2024 1:32 PM EDT

Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain.

In this article: LLY, NVO, WW

Read

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities

Article By: ChinaBio® Today

Saturday, March 23, 2024 2:00 PM EDT

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

In this article: MRK, NVO, BGNE, WXXWY, IVBXF, WUXIF Also: NVS, CTLT

Read

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates

Article By: Zacks Investment Research

Saturday, March 9, 2024 1:40 PM EDT

This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung cancer medicine, Rybrevant, for first-line use.

In this article: AZN, JNJ, NVO, RHHBY, ALNY Also: MRK, PFE

Read